Wolverine Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Wolverine Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15	Closed	-$1.52K	–	1890
2023 Q1	$1.52K	Buy	+15	New	+$1.56K	﹤0.01%	1677
2021 Q3	–	Sell	-1,994	Closed	-$194K	–	2222
2021 Q2	$194K	Buy	1,994 +1,794	+897%	+$172K	﹤0.01%	1272
2021 Q1	$19K	Sell	200 -215	-52%	-$22.5K	﹤0.01%	1774
2020 Q4	$39K	Buy	+415	New	+$40.1K	﹤0.01%	1369
2020 Q3	–	Sell	-15	Closed	-$1K	–	1701
2020 Q2	$1K	Buy	+15	New	+$1.66K	﹤0.01%	1494
2019 Q1	–	Sell	-2,432	Closed	-$173K	–	1608
2018 Q4	$173K	Buy	+2,432	New	+$233K	﹤0.01%	1267

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wolverine Asset Management's NBIX Position: Q2 2023 in Review

Wolverine Asset Management sold out of Neurocrine Biosciences (NBIX) in Q2 2023, closing a stake of 15 shares — an estimated $1.52K sold.

Wolverine Asset Management first reported a position in NBIX in Q4 2018 and held it in 6 quarters. The position peaked at $194K in Q2 2021. 456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

Wolverine Asset Management reported no remaining Neurocrine Biosciences position as of Q2 2023 after selling out during the quarter.
Wolverine Asset Management sold 15 Neurocrine Biosciences shares in Q2 2023, an estimated $1.52K.
Wolverine Asset Management first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 6 quarters.
Wolverine Asset Management's Neurocrine Biosciences position peaked at $194K in Q2 2021.
456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on Wolverine Asset Management's 13F filing for Q2 2023, filed 7 Aug 2023.